title: HCC influence on patient survival after liver transplantation for HDV cirrhosis.
abstract: OBJECTIVE
  The effect of hepatocellular cancer (HCC) in patients transplanted for hepatitis B and D virus (HB/DV) cirrhosis is not well studied. Our aim was to study the long-term survival outcomes of patients who underwent liver transplantation for HB/DV cirrhosis with and without HCC.
  
  
  METHODS
  A total of 231 primary, adult, single- organ liver transplants were performed from 1990 to 2007. HB/DV was the cause of cirrhosis in 36 patients. Nine patients died during the first 3 postoperative months from surgical complications. The study group comprised the remaining 27 patients. The median follow-up was 1515 days.
  
  
  RESULTS
  The mean patient survival was 3760 days (95% CI: 3013-4507). Six patients were diagnosed with HCC. The mean patient survival was 3011 days (95% CI: 2344-3679) and 4036 days (95% CI: 3002-5070) for recipients without and with HCC, respectively. For the same groups, the incidence of microbial infections was 61.9% and 33.3%, respectively (p=0.219). HCC has not recurred in any of the six patients.
  
  
  CONCLUSIONS
  The mean long-term survival after liver transplantation for HB/DV and HCC surpassed 11 years. The superior survival of HCC patients is difficult to explain. The increased number (almost double) of microbial infections in the non- HCC population might be held accountable.
authors.affiliation: Aristotle University, Thessaloniki, Greece.
authors.forename: Georgios
authors.initials: G
authors.lastname: Imvrios
authors.forename: Dionisios
authors.initials: D
authors.lastname: Vrochides
authors.forename: Vasilios
authors.initials: V
authors.lastname: Papanikolaou
authors.forename: Ioannis
authors.initials: I
authors.lastname: Fouzas
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Antoniadis
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Giakoustidis
authors.forename: Achilleas
authors.initials: A
authors.lastname: Ntinas
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Kardassis
authors.forename: Evangelos
authors.initials: E
authors.lastname: Akriviadis
authors.forename: Themistokles
authors.initials: T
authors.lastname: Vasiliadis
authors.forename: Ioannis
authors.initials: I
authors.lastname: Goulis
authors.forename: Eleni
authors.initials: E
authors.lastname: Katsika
authors.forename: Georgios
authors.initials: G
authors.lastname: Moutsianos
authors.forename: Kalliopi
authors.initials: K
authors.lastname: Patsiaoura
authors.forename: Georgios
authors.initials: G
authors.lastname: Tsoulfas
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Takoudas
mesh_terms: D000293:Adolescent; D000328:Adult; D006528:Carcinoma, Hepatocellular / Q000601:surgery* / Q000821:virology*; D016009:Chi-Square Distribution; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006509:Hepatitis B / Q000150:complications*; D003699:Hepatitis D / Q000150:complications*; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications* / Q000821:virology*; D008113:Liver Neoplasms / Q000601:surgery* / Q000821:virology*; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D018709:Statistics, Nonparametric; D015996:Survival Rate; D016896:Treatment Outcome